7 completed, 2 terminated, 2 unknown, 1 withdrawn. 12 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 7, Terminated 2, Unknown 2, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
Follow Hemophilia: new trials by email Literature Review of Hemophilia trials Research Report on Hemophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment SS109 - Male, Hemophilia A With Inhibitor | Phase 1 / Phase 2 | Completed | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 24 | 2023-10-12 | 2024-07-19 |
| A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient MG1113 - Hemophilia | Phase 1 | Completed | GC Biopharma Corp | 15 | 2022-08-24 | 2025-11-24 |
| Combination Regimen With Sodium Valproate for Severe Hemophilia: a Single-arm, Phase 1, Pilot Trial. Sodium valproate extended-release tablets - Hemophilia | Phase 1 / Phase 2 | Unknown | Xue-chun Lu | 10 | 2022-04-01 | 2024-02-29 |
| A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor STSP-0601 for Injection - Hemophilia | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 77 | 2021-10-12 | 2024-09-19 |
| A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor STSP-0601 for Injection - Hemophilia | Phase 1 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 16 | 2020-01-15 | 2024-09-19 |
| Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia BAY1093884 - Hemophilia | Phase 1 | Withdrawn | Bayer | 2019-10-28 | 2019-10-22 | |
| A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients MG1113, Placebo of MG1113 - Hemophilia | Phase 1 | Completed | Green Cross Corporation | 41 | 2019-01-21 | 2021-10-26 |
| Allogenic Bone Marrow Derived Mesenchymal Stem Cell Therapy in Cases of Hemophilia Cellular therapy, cellular therapy - Hemophilia | Phase 1 | Unknown | Cairo University | 20 | 2014-08-01 | 2014-04-09 |
| Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis Bevacizumab intra-articular injection - Hemophilia, Synovitis | Phase 1 | Terminated | National Taiwan University Hospital | 5 | 2014-02-01 | 2021-07-06 |
| Viral Kinetics in HCV Clearance in Subjects With Hemophilia PegInterferon, Ribavirin, Telaprevir - Chronic Hepatitis C, Hemophilia | Phase 1 | Completed | Kenneth Sherman | 5 | 2012-12-01 | 2015-04-06 |
| A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B rhFVIIa - Hemophilia | Phase 1 | Completed | rEVO Biologics | 15 | 2012-10-01 | 2013-07-30 |
| First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients placebo control, ARC19499 - Hemophilia | Phase 1 | Terminated | Baxalta now part of Shire | 17 | 2010-09-15 | 2021-05-05 |
Hemophilia A (12) · Hemophilia B (2) · Hepatitis C (1) · Hepatitis C, Chronic (1) · Synovitis (1)
Blood Coagulation Disorders (12) · Blood Coagulation Disorders, Inherited (12) · Coagulation Protein Disorders (12) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12) · Genetic Diseases, Inborn (12) · Hematologic Diseases (12) · Hemic and Lymphatic Diseases (12) · Hemorrhagic Disorders (12) · Genetic Diseases, X-Linked (2) · Blood-Borne Infections (1) · Chronic Disease (1) · Communicable Diseases (1) · Digestive System Diseases (1) · Disease Attributes (1) · Flaviviridae Infections (1)
Injections (2) · ARC19499 (1) · Bevacizumab (1) · Calcitriol (1) · Cell- and Tissue-Based Therapy (1) · Factor VII (1) · Injections, Intra-Articular (1) · Ribavirin (1) · Sirolimus (1) · telaprevir (1)
Staidson (Beijing) Biopharmaceuticals Co., Ltd (2) · Baxalta now part of Shire (1) · Bayer (1) · Cairo University (1) · GC Biopharma Corp (1) · Green Cross Corporation (1) · Hangzhou Gensciences Biopharmaceutical Co., Ltd. (1) · Kenneth Sherman (1) · National Taiwan University Hospital (1) · Xue-chun Lu (1) · rEVO Biologics (1)
China (4) · South Korea (2) · United States (2) · Egypt (1) · Netherlands (1) · Taiwan (1) · United Kingdom (1)
Eun-Jin Choi (1) · Ji-Young Park, MD (1) · Johan Frieling, MD,PhD (1) · Kenneth E Sherman, MD, PhD (1) · Lei Zhang (1) · Lei Zhang, Ph.D (1) · Shang-Ju Wu, MD (1) · Wael Abou El-Kheir, M.D. (1) · Xuechun Lu, M.D. (1)
PMID 36796484, PMID 17090654, PMID 19127265, PMID 22149959, PMID 23855900, PMID 23863832, PMID 27392538, PMID 29224506, PMID 31011710, PMID 40674256, PMID 41637644, PMID 42757060
2018 (1), R34HL109334 (1)